A prognostic multigene classifier for squamous cell carcinomas of the larynx

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 37-46

  Mirisola, Valentina ^a   Mora, Renzo ^b   Esposito, Alessia Isabella ^a   Guastini, Luca ^b   Tabacchiera, Flavia ^a   Paleari, Laura ^a   Amaro, Adriana ^a   Angelini, Giovanna ^a   Dellepiane, Massimo ^b   Pfeffer, Ulrich ^a   Salami, Angelo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Gene expression profiling; Imprinting; Laryngeal cancer; Molecular classification

Indexed keywords

HISTONE; HISTONE HIST1H3F; SMALL NUCLEOLAR RNA; SNORA16A; SNORD14C; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOME IMPRINTING; H19 GENE; HUMAN; LARYNX CARCINOMA; MALE; MICROARRAY ANALYSIS; NFKB2 GENE; ONCOGENE; PRIORITY JOURNAL; RELA GENE; RELB GENE; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LARYNGEAL NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79957473966     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.013     Document Type: Article

References (62)

1. Mayne S.T., Cartmel B., Kirsh V., Goodwin W.J. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3368-3374.
2. Rodrigues R.B., Motta Rda R., Machado S.M., Cambruzzi E., Zettler E.W., Zettler C.G., Jotz G.P. Prognostic value of the immunohistochemistry correlation of Ki-67 and p53 in squamous cell carcinomas of the larynx. Braz. J. Otorhinolaryngol. 2008, 74:855-859.
3. The Department of Veterans Affairs Laryngeal Cancer Study Group, Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer, N. Engl. J. Med. 324 (1991) 1685-1690.
4. Weber R.S., Berkey B.A., Forastiere A., Cooper J., Maor M., Goepfert H., Morrison W., Glisson B., Trotti A., Ridge J.A., Chao K.S., Peters G., Lee D.J., Leaf A., Ensley J. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch. Otolaryngol. Head Neck Surg. 2003, 129:44-49.
5. Forastiere A.A., Goepfert H., Maor M., Pajak T.F., Weber R., Morrison W., Glisson B., Trotti A., Ridge J.A., Chao C., Peters G., Lee D.J., Leaf A., Ensley J., Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003, 349:2091-2098.
6. Hoffman H.T., Porter K., Karnell L.H., Cooper J.S., Weber R.S., Langer C.J., Ang K.K., Gay G., Stewart A., Robinson R.A. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006, 116:1-13.
7. Wolf G.T. Reexamining the treatment of advanced laryngeal cancer: the VA laryngeal cancer study revisited. Head Neck 2010, 32:7-14.
8. Olsen K.D. Reexamining the treatment of advanced laryngeal cancer. Head Neck 2010, 32:1-7.
9. Forastiere A.A. Larynx preservation and survival trends: should there be concern?. Head Neck 2010, 32:14-17.
10. Yurut-Caloglu V., Caloglu M., Turan F.N., Ibis K., Karagol H., Kocak Z., Uzal C. The better performance status, the better outcome: laryngeal carcinoma treated with definitive radiotherapy. J. Otolaryngol. Head Neck Surg. 2008, 37:799-806.
11. Akman F.C., Dag N., Ataman O.U., Ecevit C., Ikiz A.O., Arslan I., Sarioglu S., Ada E., Kinay M. The impact of treatment center on the outcome of patients with laryngeal cancer treated with surgery and radiotherapy. Eur. Arch. Otorhinolaryngol. 2008, 265:1245-1255.
12. Bektas-Kayhan K., Unur M., Yaylim-Eraltan I., Ergen A., Hafiz G., Karadeniz A., Isbir T. Role of L-MYC polymorphism in oral squamous cell carcinoma in Turkey. Anticancer Res. 2009, 29:2519-2524.
13. Gold K.A., Kim E.S. Role of molecular markers and gene profiling in head and neck cancers. Curr. Opin. Oncol. 2009, 21:206-211.
14. Hu H., Zhang S., Zhu S. Influence of aspirin and cigarette smoke extract on the expression of cyclin D1 and effects of cell cycle in esophageal squamous cell carcinoma cell line. Dis. Esophagus 2009, 22:310-316.
15. Kourelis K., Vandoros G., Kourelis T., Papadas T., Goumas P., Sotiropoulou-Bonikou G. Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression. Laryngoscope 2009, 119:1723-1729.
16. Rogers S.J., Box C., Chambers P., Barbachano Y., Nutting C.M., Rhys-Evans P., Workman P., Harrington K.J., Eccles S.A. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. J. Pathol. 2009, 218:122-130.
17. Makitie A.A., Monni O. Molecular profiling of laryngeal cancer. Expert Rev. Anticancer Ther. 2009, 9:1251-1260.
18. Jarvinen A.K., Autio R., Haapa-Paananen S., Wolf M., Saarela M., Grenman R., Leivo I., Kallioniemi O., Makitie A.A., Monni O. Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene 2006, 25:6997-7008.
19. Belbin T.J., Singh B., Barber I., Socci N., Wenig B., Smith R., Prystowsky M.B., Childs G. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res. 2002, 62:1184-1190.
20. Snijders A.M., Schmidt B.L., Fridlyand J., Dekker N., Pinkel D., Jordan R.C., Albertson D.G. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005, 24:4232-4242.
21. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., Lightfoot S., Menzel W., Granzow M., Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006, 7:3.
22. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., Hornik K., Hothorn T., Huber W., Iacus S., Irizarry R., Leisch F., Li C., Maechler M., Rossini A.J., Sawitzki G., Smith C., Smyth G., Tierney L., Yang J.Y., Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
23. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., Li J., Thiagarajan M., White J.A., Quackenbush J. TM4 microarray software suite. Methods Enzymol. 2006, 411:134-193.
24. Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl Acad. Sci. USA 2002, 99:6567-6572.
25. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
26. Jaakkola T., Haussler D. Exploiting generative models in discriminative classifiers. Advances in Neural Information Processing Systems 1998, 487-493. MIT Press, Boston. M. Kearns, S. Solla, D. Cohn (Eds.).
27. Kira K., Rendel L. The feature selection problem: traditional methods and a new algorithm. Tenth National Conference on Artificial Intelligence 1992, 129-134. MIT Press, San José, CA. A. Press (Ed.).
28. Perez-Enciso M., Tenenhaus M. Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach. Hum. Genet. 2003, 112:581-592.
29. Steyerberg E.W., Eijkemans M.J., Habbema J.D. Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J. Clin. Epidemiol. 1999, 52:935-942.
30. Mood A. The distribution theory of Runs. Ann. Math. Statistics 1940, 11:367-392.
31. Bachmeier B.E., Mohrenz I.V., Mirisola V., Schleicher E., Romeo F., Hohneke C., Jochum M., Nerlich A.G., Pfeffer U. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 2008, 29:779-789.
32. Mueller P.Y., Janovjak H., Miserez A.R., Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 2002, 32:1372-1378.
33. Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr. Top. Microbiol. Immunol. 2008, 321:59-83.
34. Mineta H., Ogino T., Amano H.M., Ohkawa Y., Araki K., Takebayashi S., Miura K. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res. 1998, 18:4765-4768.
35. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat. Rev. Cancer 2007, 7:545-553.
36. Sotiriou C., Lothaire P., Dequanter D., Cardoso F., Awada A. Molecular profiling of head and neck tumors. Curr. Opin. Oncol. 2004, 16:211-214.
37. Loyo M., Pai S.I. The molecular genetics of laryngeal cancer. Otolaryngol. Clin. North Am. 2008, 41:657-672,.
38. Albini A., Mirisola V., Pfeffer U. Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. Cancer Metastasis Rev. 2008, 27:75-83.
39. Barry W.T., Kernagis D.N., Dressman H.K., Griffis R.J., Hunter J.D., Olson J.A., Marks J.R., Ginsburg G.S., Marcom P.K., Nevins J.R., Geradts J., Datto M.B. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010.
40. Pfeffer U., Romeo F., Noonan D.M., Albini A. Prediction of breast cancer metastasis by genomic profiling: where do we stand?. Clin. Exp. Metastasis 2009, 26:547-558.
41. Geisler S.A., Olshan A.F. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am. J. Epidemiol. 2001, 154:95-105.
42. Harty L.C., Caporaso N.E., Hayes R.B., Winn D.M., Bravo-Otero E., Blot W.J., Kleinman D.V., Brown L.M., Armenian H.K., Fraumeni J.F., Shields P.G. Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J. Natl. Cancer Inst. 1997, 89:1698-1705.
43. Canto M.T., Devesa S.S. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol. 2002, 38:610-617.
44. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010, 11:781-789.
45. Moulton T., Crenshaw T., Hao Y., Moosikasuwan J., Lin N., Dembitzer F., Hensle T., Weiss L., McMorrow L., Loew T., et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat. Genet. 1994, 7:440-447.
46. Steenman M.J., Rainier S., Dobry C.J., Grundy P., Horon I.L., Feinberg A.P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 1994, 7:433-439.
47. Zhang Y., Shields T., Crenshaw T., Hao Y., Moulton T., Tycko B. Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. Am. J. Hum. Genet. 1993, 53:113-124.
48. Cui H., Hedborg F., He L., Nordenskjold A., Sandstedt B., Pfeifer-Ohlsson S., Ohlsson R. Inactivation of H19, an imprinted and putative tumor repressor gene, is a preneoplastic event during Wilms' tumorigenesis. Cancer Res. 1997, 57:4469-4473.
49. Okamoto K., Morison I.M., Taniguchi T., Reeve A.E. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc. Natl Acad. Sci. USA 1997, 94:5367-5371.
50. Yoshimizu T., Miroglio A., Ripoche M.A., Gabory A., Vernucci M., Riccio A., Colnot S., Godard C., Terris B., Jammes H., Dandolo L. The H19 locus acts in vivo as a tumor suppressor. Proc. Natl Acad. Sci. USA 2008, 105:12417-12422.
51. Sparago A., Cerrato F., Vernucci M., Ferrero G.B., Silengo M.C., Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat. Genet. 2004, 36:958-960.
52. Cerrato F., Sparago A., Verde G., De Crescenzo A., Citro V., Cubellis M.V., Rinaldi M.M., Boccuto L., Neri G., Magnani C., D'Angelo P., Collini P., Perotti D., Sebastio G., Maher E.R., Riccio A. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum. Mol. Genet. 2008, 17:1427-1435.
53. Thorvaldsen J.L., Duran K.L., Bartolomei M.S. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev. 1998, 12:3693-3702.
54. Bell A.C., Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000, 405:482-485.
55. Frevel M.A., Sowerby S.J., Petersen G.B., Reeve A.E. Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor. J. Biol. Chem. 1999, 274:29331-29340.
56. Kaffer C.R., Grinberg A., Pfeifer K. Regulatory mechanisms at the mouse Igf2/H19 locus. Mol. Cell. Biol. 2001, 21:8189-8196.
57. Arney K.L. H19 and Igf2 - enhancing the confusion?. Trends Genet. 2003, 19:17-23.
58. Tsang W.P., Ng E.K., Ng S.S., Jin H., Yu J., Sung J.J., Kwok T.T. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010, 31:350-358.
59. Kiss A.M., Jady B.E., Bertrand E., Kiss T. Human box H/ACA pseudouridylation guide RNA machinery. Mol. Cell. Biol. 2004, 24:5797-5807.
60. Kiss T., Fayet-Lebaron E., Jady B.E. Box H/ACA small ribonucleoproteins. Mol Cell 2010, 37:597-606.
61. Marzluff W.F., Gongidi P., Woods K.R., Jin J., Maltais L.J. The human and mouse replication-dependent histone genes. Genomics 2002, 80:487-498.
62. Marzluff W.F., Duronio R.J. Histone mRNA expression: multiple levels of cell cycle regulation and important developmental consequences. Curr. Opin. Cell Biol. 2002, 14:692-699.